Get notified when VERU files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Company discloses uncertainty about ability to continue operations without additional financing or partnership agreements.
Veru partners with Novo Nordisk for obesity trial, grants GLP-1 combo rights
Filed June 4, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
high
Veru secured clinical supply agreement with Novo Nordisk to provide Wegovy at no charge for Phase 2b PLATEAU obesity study testing enobosarm combination therapy in older adults.
Item 1.01 view on EDGAR → -
high
Veru granted Novo Nordisk right of first negotiation for any future development or licensing of enobosarm combined with Novo Nordisk GLP-1 products across all indications, potentially limiting future partnering flexibility.
Item 1.01 view on EDGAR → -
medium
Supply agreement includes termination-for-convenience clause allowing Novo Nordisk to exit with 60 days' notice, creating risk of trial disruption if partner withdraws before completion.
Item 1.01 Risk Factors view on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.
Partner
Trade VERU commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify